Interim report January - March 2010
(Thomson Reuters ONE) -
The Group's sales for the period amounted to SEK 131 (180) million.
EBITDA amounted to SEK 18 (28) million.
Operating profit totalled SEK 11 (23) million.
The net profit after tax for the period amounted to SEK -3 (9) million
Earnings per share after tax for the period were SEK -0.01 (0.03 ) before and
after dilution
Significant events during the period
The Board decided to initiate a process to review the communicated financial
targets.
Significant events after the period
The Board has appointed Maris Hartmanis as BioPhausia's new CEO.
Niklas Prager has been proposed as the new Chairman of the Board of BioPhausia.
BioPhausia has become the main supplier of parallel-imported pharmaceuticals to
Apoteksgruppen
[HUG#1414656]
BioPhausia Interim report: http://hugin.info/130049/R/1414656/365990.pdf
Unternehmensinformation / Kurzprofil:
Datum: 11.05.2010 - 10:45 Uhr
Sprache: Deutsch
News-ID 20665
Anzahl Zeichen: 0
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 200 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Interim report January - March 2010"
steht unter der journalistisch-redaktionellen Verantwortung von
BioPhausia AB (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
